LATEST TRIALS

  • Breast Cancer
    A Phase 1b Study to Evaluate safety and clinical activity of Pembrolizumab (MK-3475) in combination with Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) – (KEYNOTE 173)
  • Solide Tumores
    An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination with Radiotherapy in Patients with Advanced Solid Tumors
  • Leukemia
    A randomized, open label, phase 2 study of the selective inhibitor of nuclear export (sine) selinexor (kpt-330) versus specified physician’s choice in patients ≥ 60 years old with relapsed/refractory acute myeloid leukemia (aml) who are ineligible for int

NORDIC COOPERATION

Norway Norway Sweden Finland Aarhus Herlev Copenhagen